obesity – Medxy AI

Enhanced Therapeutic Outcomes in Overweight/Obese Women with PCOS: Combining Metformin and Semaglutide

By MedXY 09/16/2025

Combination therapy with metformin and semaglutide improves weight loss, metabolic parameters, menstrual function, and natural pregnancy rates in overweight/obese women with PCOS compared to metformin alone.

Clinical Updates Wellness & Lifestyle

Impact of Diabetes and Obesity on Early Rhythm Control Outcomes in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial

By MedXY 09/10/2025

A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.

Clinical Updates Wellness & Lifestyle

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

By MedXY 09/07/2025

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerability.

Clinical Updates Wellness & Lifestyle

Once-Weekly Semaglutide 2.4 mg for Obesity Management in Asian Adults: Efficacy, Safety, and Policy Insights from the STEP 11 Trial

By MedXY 09/07/2025

The STEP 11 trial demonstrates that once-weekly semaglutide 2.4 mg significantly reduces bodyweight in Asian adults with obesity (BMI ≥25 kg/m²), supporting its safety and guideline inclusion in these populations with unique BMI thresholds.

Clinical Updates Wellness & Lifestyle

Injectable GLP-1 Use Soars Among US Adults with Diabetes: Trends and Clinical Implications

By MedXY 09/07/2025

Nearly 1 in 4 US adults with diabetes used injectable GLP-1 receptor agonists in 2024, reflecting rising adoption for glycemic control and obesity management with notable demographic disparities.

Medical News Wellness & Lifestyle

The Hidden Battle in Our Brain: Why We Can’t Resist Hedonic Eating

By MedXY 08/31/2025

Discover how dopamine neurons in the brain's reward center overpower satiety signals, driving hedonic eating even when we're full, revealing new insights for obesity treatment.

Clinical Updates Wellness & Lifestyle

GLP-1 Receptor Agonists in Obesity: Emerging Evidence for Cancer Risk Modulation

By MedXY 08/31/2025

GLP-1 receptor agonists, used for obesity and type 2 diabetes management, are linked to a 17% lower overall cancer risk, notably hormone-sensitive cancers, but may increase kidney cancer risk. Further research is needed to clarify safety and mechanisms.

Clinical Updates Wellness & Lifestyle

Epicardial Adipose Tissue as a Predictor of New-Onset Atrial Fibrillation: Insights from a Danish Population Cohort

By MedXY 08/30/2025

This Danish cohort study demonstrates that increased epicardial adipose tissue volume independently elevates the risk of new-onset atrial fibrillation, highlighting the importance of fat distribution beyond BMI in cardiovascular risk assessment.

Clinical Updates Wellness & Lifestyle

Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial

By MedXY 08/30/2025

Tirzepatide significantly improves health-related quality of life alongside weight reduction in adults with obesity or overweight, especially those experiencing physical function limitations, according to SURMOUNT-3 trial results.

Clinical Updates Wellness & Lifestyle

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial

By MedXY 08/30/2025

Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.